European Archives - Page 869 of 981 - European Medical Journal

EMJ Respiratory 3 [ePrint] 2015

Postoperative respiratory failure (RF) is a common problem following all types of major surgery, and which has significant implications for morbidity…

EMJ

Genes Could Be the Answer to Pain Prediction

INFLUENCE of osteoarthritis genetics may be key to pain sensitivity, according to a recent study following 122 patients with knee osteoarthritis. The…

EMJ

Pain Persists in Treated Rheumatoid Arthritis Patients

NEW research has revealed that pain persists in >50% of rheumatoid arthritis (RA) patients treated with methotrexate for 3 months, even in those who…

EMJ

Artificial Intelligence May Help Override Fearful Memories

SCIENTISTS have created a procedure that can remove specific fearful memories from the brain, which could be used as a new therapy for treating…

EMJ

First Patients Enrolled and Dosed in the Pivotal Trial of Phase 3 of the Immunotherapy Tedopi® for Advanced Non-Small Cell Lung Cancer

Paris, February 22nd, 2016, 6:30pm – OSE Pharma SA (ISIN: FR0012127173; Mnémo: OSE), an immunooncology company with a specific immunotherapy…

EMJ

Patient Enrolment Completed in US Phase IIb Study of GrassMATAMPL

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces it has completed…

EMJ

The E. Coli Anchor: The Achilles Heel of Urinary Tract Infections

NEW vaccines could soon be developed to combat urinary tract infections (UTI), following research that has provided a detailed view of a spring-like…

EMJ

Prostate Cancer Discovery May Lead to New Cancer Treatment

AN EXCITING discovery highlighting a link between two prostate cancer treatments has provided the basis for a potential new therapy. In addition…

EMJ

Overview of a Phase I study of ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase I study of ONO/GS-4059, a…

EMJ

Norgine Launches XIFAXAN® 200mg (aifaximin-α) for the Treatment of Travellers Diarrhoea in Australia

LONDON, UK, Friday 19 February, 12:00 GMT: Norgine B.V. has today announced that XIFAXAN® 200mg is now available in Australia for the treatment of…